At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 27 enrolled
Drug / intervention
Azilsartan +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Open-label, Multicenter, Long-term Study to Evaluate the Safety, Efficacy and Pharmacokinetics of TAK-536 in Pediatric Patients 6 to Less Than 16 Years of Age With Hypertension
In Brief
A Phase 3 clinical trial evaluating Azilsartan and Placebo for Pediatric Hypertension. Completed, enrolled 27 participants across 30 sites.
Detailed Summary
The purpose of this study is to evaluate the safety of administration of azilsartan in pediatric patients aged 6 to less than 16 years with hypertension.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPediatric Hypertension
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedJun 2016
Enrollment StartAug 2016
Primary CompletionJun 2019
TodayJul 2026
First PostedJun 6, 2016
Enrollment StartAug 18, 2016
Primary CompletionJun 4, 2019
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 10.1 years ago
Interventions
Azilsartandrug
Azilsartan granules and tablets
Placebodrug
Placebo-matching azilsartan granules and tablets